Please select the option that best describes you:
How do you decide between radioligand therapy or cytotoxic chemotherapy in patients with metastatic castration-resistant prostate cancer with prior ARPI exposure who have cancer-related anemia?
Given that both carry risks of worsening anemia, and both potentially may help the anemia if disease-related, how do you come up with your decision? How do you provide supportive care throughout the process?
Answer from: Medical Oncologist at Academic Institution
Radioligand therapy (presumably the question refers to Lu-177 vipivotide tetraxaten/Pluvicto) is one of the latest and most promising treatments for mCRPC. As in all cancer treatments, the practitioner needs to have a good understanding of adverse event likelihood, but also the potential for benefit...
Sign in or Register to read more